Drug Profile
ABvac 40
Alternative Names: ABvac40Latest Information Update: 26 Oct 2023
Price :
$50
*
At a glance
- Originator Araclon Biotech
- Class Alzheimer vaccines; Nootropics; Peptide vaccines
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 26 Oct 2023 Efficay and adverse events data from a phase II trial in Alzheimer's Disease released by Araclon Biotech
- 23 Mar 2023 Araclon Biotech completes the phase II trial in Alzheimer's Disease in France, Italy, Spain and Sweden (SC, injection) (NCT03461276)
- 15 Mar 2022 Adverse events and immunogenicity data from a phase-II trial in Alzheimer's disease released by Araclon Biotech